Fairvalue-Calculator Fairvalue-Calculator
EN DE

Merck & Co (MRCK34) Fair Value & Analysis

Healthcare · BR · Market cap R$1.5T

PriceR$75.80
Fair ValueR$13.54
Upside-82.1%
Quality95/100
Evidence: High Range R$7.91 – R$20.70

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Merck & Co (MRCK34) currently trades at R$75.80, while our model-based Fair Value estimate is R$13.54 — implying the stock looks roughly 82.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, S…

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -29% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% AstraZeneca PLC (A1ZN34) -31% Novartis AG (N1VS34) -9%

Frequently asked questions

Is Merck & Co (MRCK34) undervalued?
As of Jun 24, 2026, our model estimates a fair value of R$13.54 versus a price of R$75.80 — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MRCK34?
Our 21-model fair value for Merck & Co is R$13.54 (as of Jun 24, 2026), built from audited fundamentals. The current price is R$75.80.
What is the quality score of MRCK34?
Merck & Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.